Biogen Idec (NASDAQ:BIIB) recently announced the launch of Fampyra in Canada. Fampyra gained approval in Canada in February 2012 for the symptomatic improvement of walking ability in adult multiple sclerosis (MS) patients.
Biogen has a licensing deal with Acorda Therapeutics, Inc. (NASDAQ:ACOR) for the development and commercialization of Fampyra in ex-US markets. Biogen is currently working on launching Fampyra in additional markets in the EU, where it gained conditional approval in July 2011.
Fampyra, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards